BlackRock Health Sciences Term Trust (NYSE:BMEZ) Announces $0.09 Monthly Dividend

Posted by Trevor Kearing on May 3rd, 2024

BlackRock Health Sciences Term Trust (NYSE:BMEZ – Get Free Report) announced a monthly dividend on Wednesday, May 1st, Zacks reports. Investors of record on Wednesday, May 15th will be given a dividend of 0.09 per share on Friday, May 31st. This represents a $1.08 dividend on an annualized basis and a yield of 7.15%. The ex-dividend date is Tuesday, May 14th.

BlackRock Health Sciences Term Trust has increased its dividend payment by an average of 16.5% per year over the last three years.

BlackRock Health Sciences Term Trust Price Performance

Shares of BMEZ stock traded up 0.26 during trading hours on Friday, reaching 15.10. The stock had a trading volume of 160,200 shares, compared to its average volume of 322,110. BlackRock Health Sciences Term Trust has a 12 month low of 12.93 and a 12 month high of 16.59. The stock’s fifty day simple moving average is 15.74 and its 200 day simple moving average is 14.95.

Insider Buying and Selling at BlackRock Health Sciences Term Trust

In other news, major shareholder Saba Capital Management, L.P. bought 93,967 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were bought at an average cost of 15.56 per share, with a total value of 1,462,126.52. Following the completion of the purchase, the insider now directly owns 18,690,059 shares in the company, valued at 290,817,318.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 1,142,444 shares of company stock worth $18,333,831 over the last three months.

About BlackRock Health Sciences Term Trust

(Get Free Report)

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.